Clinical Trial Update: Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of orteronel as monotherapy in patients with metastatic breast cancer expressing the androgen receptor has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Orteronel (Orteronel)

Snippet

Sponsor: SCRI Development Innovations, LLC | Conditions: Metastatic Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2022-06-30